Levels of paraoxonase, high-density lipoprotein and total sialic acid levels in patients with polycystic ovary syndrome

Abstract

Paraoxonase (PON1) have been considered to have a role in various pathological processes, including inflammatory response, cardiovascular disease and recently also in ovarian dysfunction. We aimed to evaluate relation high density lipoprotein cholesterol (HDL) levels and PON1 activity and total sialic acid status (TSA) levels in serum of patients with polycystic ovary syndrome (PCOS) and healthy individuals.

Twenty PCOS patients (PCOS group) and 20 healthy nonhyperandrogenic women (control group) were studied in the current study. Levels of HDL, TSA, and activity of PON1 were measured in serum of PCOS patients.

Levels of PON1 activity and level of HDL were significantly lower in the PCOS group than in the control group. TSA levels were higher in the PCOS group than the control group. There was also a significant correlation between the parameters and syndrome initiation.

In conclusion, patients with PCOS had high level of PON1. It might be hypothesized that elevated serum TSA, HDL and PON1 may be associated with increased cardiovascular risk in PCOS and/or menstrual irregularities associated with this syndrome.

Keywords

• polycystic ovary syndrome,Paraoxonase,total sialic acid,high density lipoprotein,follicle stimulating hormone,reactive nitrogen species

References

1. Abdel-Wahab YH, O’Harte FP, Mooney MH, Barnett CR, Flatt PR. 2002. Vitamin C supplementation decreases insulin glycation and improves glucose homeostasis in obese hyperglycemic (ob/ob) mice. Metabolism 51: 514–517.
2. Altug Sen T, Koken R, Narci A, Yilmazer M. 2011. Homocysteine and ghrelin link with polcystic ovary syndrome in relation to obesity. J Pediatr Adolesc Gynecol 24: 211–217.
3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. 2005. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 90: 1929-1935.
4. Atiomo WU, El-Mahdi E, Hardiman P. 2003. Familial associations in women with policyctic ovary syndrome. Fertil Steril 80: 143-145.
5. Aye M , Malek S. 2012. Waist Circumference and BMI Cut-Off Points to Predict Risk Factors for Metabolic Syndrome. Singapore Med J 53(8): 545-550.
6. Balen AH, Conway GS, Kaltsas G. Techatrasak K, Manning PJ, West C, Jacobs HS. 1995. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod, 10: 2107–2111.
7. Bayram F, Kocer D, Ozsan M, Muhtaroglu S. 2012. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol Endocrinol 28: 497–501.
8. Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C, Cummings MH. 2005. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 58: 151–154.

9. Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. 2003. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med 34: 824-829.
10. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L. 2002. Factors associated with oxidative stress in human populations. Am J Epidemiol 156: 274–285.
11. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. 2006. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12: 673–683.
12. Crosignani PG, Nicolosi AE. 2001. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 7: 3-7.
13. Dincer Y, Ozen E, Kadioglu P, Hatemi H, Akçay T. 2001. Effect of sex hormones on lipid peroxidation in women with polycystic ovary syndrome, healthy women, and men. Endocr Res 27: 309–316.
14. Dursun P, Demirtas E, Bayrak A, Yarali H. 2006. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?. Hum Reprod 21: 104–108.
15. Eckerson HW, Romson J, Wyte CM, La Du BN. 1983. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet 35: 214-227.
16. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. 2010. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 109: 239-241.
17. Fauser BC, Diedrich K, Devroey P. 2008. Predictors of ovarian response: progress toward individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 14: 1-14.
18. Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N. 2008. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod 23(7): 1602-6.
19. Fenkci IV, Serteser M, Fenkci S, Kose S. 2007. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 52: 879–883.
20. Fulghesu A, Magnini R, Portoghese E, Angioni S, Minerba L, Melis GB. 2010. Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome. J Adolesc Health 46: 474–481.
21. Gulcu F, Gursu MF. 2003. The standardization of paraoxonase and arylesterase activity measurements. Turk J Biochem, 28:45-49.
22. Hangloo VK, Kaul I, Zargar HU. 1990. Serum sialic acid levels in healthy individuals. J Postgrad Med. 36:140–2.
23. Katopodis N, Hirshaut Y, Geller NL, Stock CC. 1982. Lipid-associated sialic acid test for the detection of human cancer. Cancer Res. 42: 5270–5.
24. Legro RS, Strauss JF. 2002. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78: 569-576.
25. Lindberg G, Ecklund GA, Gullberg B, Rastam L. 1991. Serum sialic acid concentration and cardiovascular mortality. BMJ. 302: 143–6.
26. Liu J, Zhang D. 2012. The role of oxidative stress in the pathogenesis of polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban. 43: 187-90.
27. Khan U. 2007. Polycystic ovary syndrome in adolescents. J Pediatr Adolesc Gynecol 20: 101-4.
28. Meyer C, McGrath BP, Teede HJ. 2007. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30: 471–8.
29. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. 2009. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci 116: 761–770.
30. Piskinpasa S, Yıldız BO. 2005. Polikistik over sendromu. Hacettepe Tıp Dergisi 36: 168-174.
31. Plucinsky Mark C, Riley WM, Prorok JJ, Alhadeff JA. 1986. Total and lipid associated serum sialic acid levels in cancer patients with different primary sites and differing degrees of metastasis involvement. Cancer 58: 2680–5.
32. Pönniö M, Alho H, Nikkari ST, Olsson U, Rydeberg U, Sillanaukee P. 1999. Serum sialic acid in a random sample of the general population. Clin Chem. 45: 1842–9.
33. Radosh L. 2009. Drug treatments for polycystic ovary syndrome. Am Fam Physician 79: 671-676.
34. Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN. 1997. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 82(10): 3389-94.
35. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O’Callaghan C, Czupryniak L. 2002. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 87: 4496–501
36. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S. 1996. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 44(3): 277-84.
37. Suer Gokmen S, Kazezoglu C, Sunar B, Ozçelik F, Güngör O, Yorulmaz F, Gülen S. 2006. Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction. Clin Chem Lab Med 44: 199-206.
38. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. 2001. Cardiovasculer risk in women with PCOS. Obstet Gynecol. 28: 111-133.
39. Teiber JF, Billecke SS, La Du BN, Draganov DI. 2007. Estrogen esters as substrates for human paraoxonases. Arch Biochem Biophys 461(1): 24-9.
40. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. 2004. Hum Reprod 19: 41–47.
41. Turan V, Erdoğan M, Yeniel Ö, Ergenoğlu M, Kazandı M. 2011. Polikistik over sendromu tanısı konmuş 89 hastanın biyokimyasal, hormonal kan parametrelerinin ve klinik bulgularının incelenmesi. Ege Tıp Dergisi 50: 179-182.
42. Turan V, Sezer ED, Zeybek B, Sendag F. 2015. Infertility and the presence of insulin resistance are associated with increased oxidative stress in young, non-obese Turkish women with polycystic ovary syndrome. Jour of Pediatr & Adoles Gynecol 28(2): 119–123.
43. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS. 2008. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 93: 470-476.
44. Zheng YH, Ding T, Ye DF, Liu H, Lai MH, Ma HX. 2015. Effect of low-frequency electroacupuncture intervention on oxidative stress and glucose metabolism in rats with polycystic ovary syndrome. Acupun Resear 40(2): 125–130.